ClinicalTrials.gg
CompletedNCT02607956Updated Mar 7, 2022Results posted

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in Human Immunodeficiency Virus (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

A Phase 3 interventional study of DTG and F/TAF in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 125 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-07.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
657
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This primary objective of this study is to evaluate the efficacy of a fixed dose combination (FDC) containing bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir alafenamide (F/TAF) in HIV-1 infected, antiretroviral treatment-naive adults.

02

Conditions studied

  • HIV-1 Infection

Keywords

  • HIV
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Antiretroviral treatment naive (≤ 10 days of prior therapy with any antiretroviral agent following a diagnosis of -1 infection) except the use for pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), up to one month prior to screening
  • Plasma HIV-1 ribonucleic acid (RNA) levels ≥ 500 copies per milliliter (mL) at screening
  • Adequate renal function: Estimated ≥ 30 mL per minute (min) (≥ 0.50 mL per second (sec)) according to the formula

Key Exclusion Criteria:

  • An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior to screening
  • Decompensated cirrhosis (eg, ascites, encephalopathy, or variceal bleeding)
  • Current alcohol or substance use judged by the Investigator to potentially interfere with subject study compliance
  • Females who are pregnant (as confirmed by positive serum pregnancy test)
  • Females who are breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
657 participants (actual)

Study arms

  • Experimental
    B/F/TAF

    B/F/TAF + DTG + F/TAF placebo administered without regard to food for at least 144 weeks.

    Drug: B/F/TAF · Drug: DTG Placebo · Drug: F/TAF Placebo

  • Active comparator
    DTG + F/TAF

    DTG + F/TAF+ B/F/TAF placebo administered without regard to food for at least 144 weeks.

    Drug: DTG · Drug: F/TAF · Drug: B/F/TAF Placebo

  • Experimental
    Open-label Phase B/F/TAF from B/F/TAF

    After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive open-label (OL) B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

  • Experimental
    Open-label Phase B/F/TAF from DTG + F/TAF

    After Week 144, participants will continue to take their blinded study drug and attend visits every 12 weeks until the End of Blinded Treatment Visit. Following the End of Blinded Treatment Visit, participants will be given the option to receive OL B/F/TAF for 96 weeks. After the Week 96 OL Visit, participants in a country where B/F/TAF is not commercially available will be given the option to continue OL B/F/TAF until the product becomes accessible through an access program or until Gilead elects to discontinue the study in that country, whichever occurs first.

    Drug: B/F/TAF

Interventions

  • DrugDTG

    50 mg tablets administered orally, once daily

    Also known as: Tivicay®

  • DrugF/TAF

    Drug pages: Emtricitabine · Tenofovir alafenamide

    200/25 mg tablets administered orally, once daily

    Also known as: Descovy®

  • DrugB/F/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    50/200/25 milligrams (mg) FDC tablets administered orally, once daily

    Also known as: GS-9883/F/TAF, Biktarvy®

  • DrugDTG Placebo

    Tablets administered orally, once daily

  • DrugF/TAF Placebo

    Tablets administered orally, once daily

  • DrugB/F/TAF Placebo

    Tablets administered orally, once daily

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  2. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 144

  3. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 48

  4. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 96

  5. Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

    The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

    Time frame: Week 144

  6. Change From Baseline in log10 HIV-1 RNA at Week 48

    Time frame: Baseline, Week 48

  7. Change From Baseline in log10 HIV-1 RNA at Week 96

    Time frame: Baseline, Week 96

  8. Change From Baseline in log10 HIV-1 RNA at Week 144

    Time frame: Baseline, Week 144

  9. Change From Baseline in CD4+ Cell Count at Week 48

    Time frame: Baseline, Week 48

  10. Change From Baseline in CD4+ Cell Count at Week 96

    Time frame: Baseline, Week 96

  11. Change From Baseline in CD4+ Cell Count at Week 144

    Time frame: Baseline, Week 144

  12. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.

    Time frame: Baseline, open-label Week 48

  13. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

    Time frame: Baseline, open-label Week 48

  14. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.

    Time frame: Baseline, open-label Week 96

  15. Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

    Time frame: Baseline, open-label Week 96

  16. Change From Baseline in CD4+ Cell Count at Week 48 Open-Label

    Time frame: Baseline, open-label Week 48

  17. Change From Baseline in CD4+ Cell Count at Week 96 Open-Label

    Time frame: Baseline, open-label Week 96

07

Results

Posted Jun 6, 2018

Participant flow

Participants were enrolled at centers in Australia, Europe, North America, and the Dominican Republic. The first participant was screened on 11 November 2015. The last study visit occurred on 05 July 2021.

Double-Blinded Phase
Participant flow — Double-Blinded Phase
MilestoneB/F/TAFDTG + F/TAFB/F/TAF to B/F/TAFDTG + F/TAF to B/F/TAF
Started32733000
Completed26627700
Not completed615300
Withdrew: Withdrew consent171900
Withdrew: Lost to follow-up191600
Withdrew: Randomized but never treated7500
Withdrew: Investigator's discretion7200
Withdrew: Death4400
Withdrew: Adverse event4300
Withdrew: Protocol violation3100
Withdrew: Non-compliance with study drug0300
Open-Label Extension Phase
Participant flow — Open-Label Extension Phase
MilestoneB/F/TAFDTG + F/TAFB/F/TAF to B/F/TAFDTG + F/TAF to B/F/TAF
Started00254265
Completed00225235
Not completed002930
Withdrew: Withdrew consent001016
Withdrew: Lost to follow-up00146
Withdrew: Death0013
Withdrew: Investigator's discretion0022
Withdrew: Non compliance with study drug0020
Withdrew: Protocol violation0002
Withdrew: Pregnancy0001

Outcome measures

PrimaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm89.492.9
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -3.5 · 95.002% CI -7.9 to 1.0Differences in percentages of participants between groups and their 95.002% CIs were calculated based on Mantel-Haenszel (MH) proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.12p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm84.186.5
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -2.3 · 95% CI -7.9 to 3.2Differences in percentages of participants between groups and their 95% CIs were calculated based on MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.41p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm81.984.0
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -1.9 · 95% CI -7.8 to 3.9Differences in percentages of participants between groups and their 95% CIs were calculated based on MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.52p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm82.287.1
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -3.9 · 95% CI -9.4 to 1.5The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.16p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 96 as Defined by the US FDA-Defined Snapshot Algorithm77.580.3
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -2.5 · 95% CI -8.8 to 3.8The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.44p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm

The percentage of participants achieving HIV-1 RNA \< 20 copies/mL at Week 144 was analyzed using the snapshot algorithm, which defines a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.

Time frame:
Week 144
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm
percentage of participantsB/F/TAFDTG + F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 20 Copies/mL at Week 144 as Defined by the US FDA-Defined Snapshot Algorithm77.579.1
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · Difference in percentages: -1.1 · 95% CI -7.4 to 5.3The differences in percentages of participants between treatment groups and their 95% CIs were calculated based on the MH proportions adjusted by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
  • B/F/TAF vs DTG + F/TAF · Cochran-Mantel-Haenszel · p = 0.74p-value was calculated from CMH test stratified by baseline HIV-1 RNA stratum (≤ 100,000 vs. \> 100,000 copies/mL) and region stratum (US vs. Ex-US).
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 48
log10 copies/mLB/F/TAFDTG + F/TAF
Change From Baseline in log10 HIV-1 RNA at Week 48-3.07 ± 0.719-3.12 ± 0.672
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.081 · Difference in lsm: 0.08 · 95% CI -0.01 to 0.17Difference in least-squares mean (LSM), and its 95% confidence interval (CI) were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 96
log10 copies/mLB/F/TAFDTG + F/TAF
Change From Baseline in log10 HIV-1 RNA at Week 96-3.08 ± 0.703-3.10 ± 0.713
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.18 · Difference in lsm: 0.06 · 95% CI -0.03 to 0.15Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in log10 HIV-1 RNA at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · log10 copies/mL
Change From Baseline in log10 HIV-1 RNA at Week 144
log10 copies/mLB/F/TAFDTG + F/TAF
Change From Baseline in log10 HIV-1 RNA at Week 144-3.06 ± 0.731-3.11 ± 0.672
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.054 · Difference in lsm: 0.09 · 95% CI 0.00 to 0.18Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 48
Time frame:
Baseline, Week 48
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 48
cells/μLB/F/TAFDTG + F/TAF
Change From Baseline in CD4+ Cell Count at Week 48180 ± 166.2201 ± 165.9
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.096 · Difference in lsm: -23 · 95% CI -49 to 4Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 96
Time frame:
Baseline, Week 96
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 96
cells/μLB/F/TAFDTG + F/TAF
Change From Baseline in CD4+ Cell Count at Week 96237 ± 204.2281 ± 209.3
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.008 · Difference in lsm: -47 · 95% CI -81 to -12Difference in LSM, and its 95% CI were adjusted by the baseline HIV-1 RNA and region stratum.
SecondaryChange From Baseline in CD4+ Cell Count at Week 144
Time frame:
Baseline, Week 144
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 144
cells/μLB/F/TAFDTG + F/TAF
Change From Baseline in CD4+ Cell Count at Week 144278 ± 236.6289 ± 218.5
Statistical analysis
  • B/F/TAF vs DTG + F/TAF · ANOVA · p = 0.48 · Difference in lsm: -14 · 95% CI -52 to 25Difference in LSM, and its 95% CI were adjusted by baseline HIV-1 RNA stratum and region stratum.
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.

Time frame:
Baseline, open-label Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm
percentage of participantsAll B/F/TAFDTG + F/TAF to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Excluded Algorithm99.2 (97.1 to 99.9)99.6 (97.5 to 100.0)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

Time frame:
Baseline, open-label Week 48
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm
percentage of participantsAll B/F/TAFDTG + F/TAF to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 48 Open-Label as Defined by Missing = Failure Algorithm75.3 (70.2 to 79.9)84.5 (79.6 to 88.7)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Excluded for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was excluded in the computation of the percentages (ie, missing data points were excluded from both the numerator and denominator in the computation). The denominator for percentages at a visit was the number of participants in the all B/F/TAF analysis set with nonmissing HIV-1 RNA value at that visit.

Time frame:
Baseline, open-label Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm
percentage of participantsAll B/F/TAFDTG + F/TAF to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Excluded Algorithm99.5 (97.5 to 100.0)99.1 (96.9 to 99.9)
SecondaryPercentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL was analyzed using Missing = Failure for imputing missing HIV-1 RNA values using the All B/F/TAF Analysis Set for the all B/F/TAF analysis. All missing data was treated as HIV-1 RNA ≥ 50 copies/mL. The denominator for percentages was the number of participants in all B/F/TAF analysis set.

Time frame:
Baseline, open-label Week 96
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm
percentage of participantsAll B/F/TAFDTG + F/TAF to B/F/TAF
Percentage of Participants Who Achieved HIV-1 RNA < 50 Copies/mL at Week 96 Open-Label as Defined by Missing = Failure Algorithm68.1 (62.7 to 73.2)87.5 (83.0 to 91.3)
SecondaryChange From Baseline in CD4+ Cell Count at Week 48 Open-Label
Time frame:
Baseline, open-label Week 48
Reported as:
Mean · cells/μL
Change From Baseline in CD4+ Cell Count at Week 48 Open-Label
cells/μLAll B/F/TAFDTG + F/TAF to B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 48 Open-Label304 ± 249.29 ± 198.0
SecondaryChange From Baseline in CD4+ Cell Count at Week 96 Open-Label
Time frame:
Baseline, open-label Week 96
Reported as:
Mean · cells/µL
Change From Baseline in CD4+ Cell Count at Week 96 Open-Label
cells/µLAll B/F/TAFDTG + F/TAF to B/F/TAF
Change From Baseline in CD4+ Cell Count at Week 96 Open-Label336 ± 235.1-10 ± 181.1

Adverse events

Collected over Adverse Events: First dose date up to last dose date (maximum: 281.4 weeks) plus 30 days All-Cause Mortality: Randomization date through last visit/follow up date (maximum: 287.1 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
B/F/TAF4/327 (1.2%)64/320 (20%)250/320 (78.1%)
DTG + F/TAF4/330 (1.2%)46/325 (14.2%)262/325 (80.6%)
B/F/TAF to B/F/TAF1/254 (0.4%)20/254 (7.9%)165/254 (65%)
DTG + F/TAF to B/F/TAF3/265 (1.1%)32/265 (12.1%)163/265 (61.5%)
Most frequent serious events
Showing 10 of 180
Most frequent serious events
EventB/F/TAFDTG + F/TAFB/F/TAF to B/F/TAFDTG + F/TAF to B/F/TAF
CellulitisInfections and infestations6/3201/3251/2542/265
PneumoniaInfections and infestations1/3204/3252/2542/265
Anal abscessInfections and infestations3/3200/3250/2540/265
AppendicitisInfections and infestations3/3202/3250/2541/265
RhabdomyolysisMusculoskeletal and connective tissue disorders3/3200/3250/2540/265
Acute kidney injuryRenal and urinary disorders3/3202/3250/2540/265
Covid-19Infections and infestations0/3200/3252/2541/265
Atrial fibrillationCardiac disorders1/3201/3250/2542/265
DeathGeneral disorders0/3202/3251/2542/265
AnaemiaBlood and lymphatic system disorders2/3200/3250/2540/265
Most frequent other events
Showing 10 of 39
Most frequent other events
EventB/F/TAFDTG + F/TAFB/F/TAF to B/F/TAFDTG + F/TAF to B/F/TAF
DiarrhoeaGastrointestinal disorders66/32054/32515/25415/265
NasopharyngitisInfections and infestations51/32062/32519/25422/265
HeadacheNervous system disorders57/32059/32516/25419/265
Upper respiratory tract infectionInfections and infestations44/32054/32515/25417/265
Back painMusculoskeletal and connective tissue disorders30/32044/32518/25412/265
NauseaGastrointestinal disorders31/32043/3258/25411/265
Covid-19Infections and infestations0/3200/32526/25431/265
FatigueGeneral disorders29/32037/3254/25413/265
ArthralgiaMusculoskeletal and connective tissue disorders36/32033/32516/25417/265
SyphilisInfections and infestations34/32033/32520/25417/265

Baseline characteristics

Safety Analysis Set included participants who were randomized into the study and received at least 1 dose of the study drug.

Age, Continuous
Age, Continuous(years)B/F/TAFDTG + F/TAFTotal
Mean37 ± 12.337 ± 11.637 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)B/F/TAFDTG + F/TAFTotal
Female403777
Male280288568
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFDTG + F/TAFTotal
American Indian or Alaska Native112
Asian71017
Black97100197
Native Hawaiian or Pacific Islander101
White183195378
Other311950
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)B/F/TAFDTG + F/TAFTotal
Hispanic or Latino8381164
Not Hispanic or Latino237244481
Region of Enrollment
Region of Enrollment(Participants)B/F/TAFDTG + F/TAFTotal
Canada12921
Belgium448
United States193193386
Dominican Republic271845
Italy151833
United Kingdom212344
Australia41014
France7512
Germany202848
Spain171734
HIV-1 RNA
HIV-1 RNA(log10 copies/mL)B/F/TAFDTG + F/TAFTotal
Mean4.39 ± 0.7304.42 ± 0.6694.41 ± 0.700
HIV-1 RNA Categories
HIV-1 RNA Categories(Participants)B/F/TAFDTG + F/TAFTotal
≤ 100,000 copies/mL254271525
> 100,000 ≤ 400,000 copies/mL544195
> 400,000 copies/mL121325
CD4 Cell Count
CD4 Cell Count(Cells/µL)B/F/TAFDTG + F/TAFTotal
Mean457 ± 255.3454 ± 231.5456 ± 243.4

1 further baseline measures are reported on the registry.

08

Study locations

125 sites
  • Phoenix, Arizona 85012, United States
  • Phoenix, Arizona 85025, United States
  • Beverly Hills, California 90211, United States
  • Los Angeles, California 90027, United States
  • Los Angeles, California 90036, United States
  • Los Angeles, California 90059, United States
  • Los Angeles, California 90069, United States
  • Sacramento, California 95817, United States
  • Sacramento, California 95825, United States
  • Optimus Medical - ClinEdge - PPDS
    San Francisco, California 94102, United States
  • Kaiser Permanente
    San Leandro, California 94577, United States
  • Denver, Colorado 80205, United States
  • Washington, District of Columbia 20009, United States
  • Washington, District of Columbia 20036, United States
  • Washington, District of Columbia 20037, United States
  • DeLand, Florida 32720, United States
  • Fort Lauderdale, Florida 33316, United States
  • Fort Pierce, Florida 34982, United States
  • Miami Beach, Florida 33139, United States
  • Miami, Florida 33133, United States
  • Miami, Florida 33136, United States
  • Oakland Park, Florida 33306, United States
  • Orlando, Florida 32803, United States
  • Pensacola, Florida 32504, United States
  • Tampa, Florida 33614, United States
  • West Palm Beach, Florida 33407, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30312, United States
  • Decatur, Georgia 30033, United States
  • Macon, Georgia 31201, United States
  • Savannah, Georgia 31405, United States
  • Chicago, Illinois 60613, United States
  • Chicago, Illinois 60657, United States
  • Indianapolis, Indiana 46202, United States
  • Sinai Hospital of Baltimore
    Baltimore, Maryland 21215, United States
  • Boston, Massachusetts 02129, United States
  • Boston, Massachusetts 02215, United States
  • Springfield, Massachusetts 01105, United States
  • Berkley, Michigan 48072, United States
  • Detroit, Michigan 48202, United States
  • Kansas City, Missouri 64111, United States
  • Saint Louis, Missouri 63108, United States
  • Saint Louis, Missouri 63139, United States
  • Hillsborough, New Jersey 08844, United States
  • Newark, New Jersey 07102, United States
  • Albany, New York 12208, United States
  • Bronx, New York 10461, United States
  • Manhasset, New York 11030, United States
  • New York, New York 10011-4121, United States
  • New York, New York 10011, United States
  • Chapel Hill, North Carolina 27514, United States
  • Charlotte, North Carolina 28207, United States
  • Cone Health Regional Center for Infectious Disease
    Greensboro, North Carolina 27401, United States
  • Greenville, North Carolina 27858-4354, United States
  • Huntersville, North Carolina 28078, United States
  • Winston-Salem, North Carolina 27157, United States
  • Cincinnati, Ohio 45267, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19107, United States
  • Allegheny Health Network
    Pittsburgh, Pennsylvania 15212, United States
  • Columbia, South Carolina 29203-6840, United States
  • Austin, Texas 78705, United States
  • Bellaire, Texas 77401, United States
  • Dallas, Texas 75202, United States
  • AIDS Arms Inc
    Dallas, Texas 75215, United States
  • Dallas, Texas 75235, United States
  • North Texas Infectious Diseases Consultants PA
    Dallas, Texas 75246, United States
  • Fort Worth, Texas 76104, United States
  • Houston, Texas 77004, United States
  • Houston, Texas 77098, United States
  • Longview, Texas 75605, United States
  • Annandale, Virginia 22003-7313, United States
  • Seattle, Washington 98104, United States
  • Spokane, Washington 99204, United States
  • Sydney, New South Wales 2010 NSW, Australia
  • Carlton, Victoria 3053, Australia
  • Clayton, Victoria 3168, Australia
  • Melbourne, Victoria 3004, Australia
  • Prahran, Victoria 3068, Australia
  • Prahran Market Clinic
    Prahran, Victoria 3181, Australia
  • Antwerp, 2000, Belgium
  • Ghent, B-9000, Belgium
  • McGill University Health Center
    Montreal, H4A 3J1, Canada
  • Ottawa, K1H 8L6, Canada
  • Sunnybrook Health Sciences Centre
    Toronto, M4N 3M5, Canada
  • Toronto, M5G 1K2, Canada
  • Toronto, M5G2N2, Canada
  • Winnipeg, R3A 1R9, Canada
  • Santo Domingo, 10103, Dominican Republic
  • Montpellier, 34295, France
  • CHU de Nice Archet I
    Nice, 06200, France
  • Tourcoing, 59200, France
  • Tourcoing, 59208, France
  • Berlin, 12157, Germany
  • Düsseldorf, 40237, Germany
  • Essen, 45122, Germany
  • Frankfurt, 60311, Germany
  • Frankfurt, 60590, Germany
  • Hamburg, 20146, Germany
  • Uniklinik Köln
    Köln, 50924, Germany

Showing the first 100 of 125 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, Garner W, Custodio J, White K, SenGupta D, Cheng A, Quirk E. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2073-2082. doi: 10.1016/S0140-6736(17)32340-1. Epub 2017 Aug 31. PubMed 28867499 ↗
  • Gupta SK, Post FA, Arribas JR, Eron JJ Jr, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, Negredo E, Elion RA, Guo S, Zhong L, Carter C, Martin H, Brainard D, SenGupta D, Das M. Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials. AIDS. 2019 Jul 15;33(9):1455-1465. doi: 10.1097/QAD.0000000000002223. PubMed 30932951 ↗
  • Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 Jun;6(6):e364-e372. doi: 10.1016/S2352-3018(19)30080-3. Epub 2019 May 5. PubMed 31068272 ↗
  • Acosta RK, Willkom M, Martin R, Chang S, Wei X, Garner W, Lutz J, Majeed S, SenGupta D, Martin H, Quirk E, White KL. Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks. Antimicrob Agents Chemother. 2019 Apr 25;63(5):e02533-18. doi: 10.1128/AAC.02533-18. Print 2019 May. PubMed 30803969 ↗
  • Acosta R, Willkom M, Martin R, Chang S, Liu X, Hedskog C, et al. Low-frequency resistance variants in ART-naive participants do not affect bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) triple therapy outcome. [Poster MOPEB242]. 10th IAS Conference on HIV Science (IAS 2019); 2019 July 21-24; Mexico City, Mexico.
  • Johnson M, Taylor S, Wei X, Collins SE, Martin H. Hepatic Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide [Poster P061]. 25th Annual Conference of the British HIV Association; 2019 02-05 April; Bournemouth, United Kingdom.
  • Gupta S, Mills A, Brinson C, Workowski K, Clarke A, Antinori A, et al. 96 Week Efficacy and Safety of B/F/TAF in Treatment-Naïve Adults and Adults ≥50 Years [Poster 502]. CROI 2019; 2019 04-07 March; Seattle, WA.
  • Acosta R, White K, Garner W, Wei X, Andreatta K, Willkom M, et al. HIV-1 subtype (B or non-B) had no impact on the efficacy of B/F/TAF or resistance development in five phase 3 treatment-naïve or switch studies. [Poster THPEB077]. 22nd International AIDS Conference; 2018 July 23-27; Amsterdam, Netherlands.
  • White K, Kulkarni R, Willkom M, Martin R, Chang S, Wei X, et al. Pooled week 48 efficacy and baseline resistance: B/F/TAF in treatment-naive patients. [Poster 532]. Conference on Retroviruses and Opportunistic Infections; 2018 March 4-7; Boston, USA.
  • Wohl D, Clarke A, Maggiolo F, Garner W, Laouri M, Martin H, Quirk E. Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine. Patient. 2018 Oct;11(5):561-573. doi: 10.1007/s40271-018-0322-8. PubMed 29956087 ↗
  • Wohl DA, Yazdanpanah Y, Baumgarten A, Clarke A, Thompson MA, Brinson C, Hagins D, Ramgopal MN, Antinori A, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 Jun;6(6):e355-e363. doi: 10.1016/S2352-3018(19)30077-3. Epub 2019 May 5. PubMed 31068270 ↗
  • Acosta R, Andreatta K, D'Antoni M, Collins S, Martin H, White K. HIV Viral Blips in Adults Treated with INSTI-Based Regimens Through 144 Weeks. [Poster 540]. Conference on Retroviruses and Opportunistic Infections 2020 (CROI 2020); 2020 March 8-11; Boston, Massachusetts.
  • Mills A, Gupta SK, Brinson C, Workowski K, Clarke A, Antinori A, Stephens JL, et al. 144-Week Efficacy and Safety of B/F/TAF in Treatment-Naive Adults Age ≥50 Years. [Poster 477]. Conference on Retroviruses and Opportunistic Infections 2020 (CROI 2020); 2020 March 8-11; Boston, Massachusetts.
  • Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, Clarke A, Huang H, Acosta R, Brainard DM, Collins SE, Martin H; GS-US-380-1489; GS-US-380-1490 study investigators. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. Lancet HIV. 2020 Jun;7(6):e389-e400. doi: 10.1016/S2352-3018(20)30099-0. PubMed 32504574 ↗
  • Ramgopal M, Maggiolo F, Ward D, Leboucche B, Rizzardini G, Molina JM, et al. Pooled Analysis of 4 International Trials of Bictegravir/Emtrictabine/Tenofovir Alafenamide (B/F/TAF) in Adults Aged ≥ 65 Years Demonstrating Safety and Efficacy: Week 48 Results. [Oral OAB0403].AIDS 2020; 2020 July 6-10; Virtual.
  • Acosta R, Andreatta K, D'Antoni M, Collins S, Martin H, White K. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) shows high efficacy in clinical study participants infected with HIV-1 subtype F. [Poster P124]. HIV Drug Therapy 2020 (HIV Glasgow 2020); 2020 October 5-8; Glasgow, United Kingdom.
  • Acosta R, Chen G, Chang S, Martin R, Wang X, Huang H, et al. HIV with Transmitted Drug Resistance Is Durably Suppressed by B/F/TAF at Week 144. [Poster 430]. Conference on Retroviruses and Opportunistic Infections 2021 (CROI 2021); 2021 June 3-November 3; Virtual.
  • Acosta RK, Chen GQ, Chang S, Martin R, Wang X, Huang H, Brainard D, Collins SE, Martin H, White KL. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants. J Antimicrob Chemother. 2021 Jul 15;76(8):2153-2157. doi: 10.1093/jac/dkab115. PubMed 33880558 ↗
  • Workowski K, Orkin C, Sax P, Hagins D, Koenig E, Stephens JL, et al. Four-Year Outcomes of B/F/TAF in Treatment-Naïve Adults [Poster 415]. Conference on Retroviruses and Opportunistic Infections 2021 (CROI 2021); 2021 June 3-November 3; Virtual.
  • Acosta R, Chen G, Qin L, Wang X, Huang H, Hindman J, et al. Achievement of Undetectable HIV-1 RNA in the B/F/TAF Treatment-Naive Clinical Trials. [Poster PEB150]. 11th IAS Conference on HIV Science (IAS 2021); 2021 July 18-21; Virtual.
  • Acosta R, Chen G, Huang H, Liu H, White K. Unreturned Pill Bottles in the 1489 and 1490 Clinical Trials: An Important Measure of Poor Adherence That Is Often Ignored in Pill Count Calculations. [Poster 902]. IDWeek 2021; 2021 September 29-October 3; Virtual.
  • Arribas J, Orkin C, Maggiolo F, Antinori A, Lazzarin A, Yasdanpanah, et al. Long-term Analysis of B/F/TAF in Treatment-Naïve Adults Living With HIV Through Four Years of Follow-up. [PEB151]. 11th IAS Conference on HIV Science (IAS 2021); 2021 July 18-21; Virtual.
  • Daar E, Orkin C, Sax P, Stephens J, Koenig E, Clarke A, et al. Incidence of Metabolic Complications Among Treatment-naïve Adults Living With HIV-1 Randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF After 3 Years. [Oral 69]. IDWeek 2021; 2021 September 29- October 3; Virtual.
  • Pozniak A, et al. Outcomes 48 Weeks After Switching From DTG/ABC/3TC or DTG+F/TAF to B/F/TAF. [PE2/68]. 18th European AIDS Conference (EAC 2021), 2021 October 27-30; London, United Kingdom.

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy

Supporting information: Study protocol, Statistical analysis plan

Time frame: 18 months after study completion

Access criteria: A secured external environment with username, password, and RSA code.

Data sharing details ↗ · www.gilead.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in May 2017, 18 months.

Results were first posted in Jun 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2015
First posted
Nov 18, 2015
StartActual
Nov 11, 2015
Primary completionActual
May 12, 2017
CompletionActual
Jul 5, 2021
Results first posted
Jun 6, 2018
Last update
Mar 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02607956
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 11, 2015
Primary completion
May 12, 2017
Completion
Jul 5, 2021
Results posted
Jun 6, 2018
Last update
Mar 7, 2022

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Emtricitabine · Tenofovir alafenamide · Bictegravir

Start the discussion